BIOMAT Database Logo BIOMAT Database Logo

[A study of urinary tegafur, 5-fluorouracil (5-FU) and uracil concentrations in the cases of gastric carcinoma for the confirmation of drug-taking compliance after UFT oral administration]. 1992

S Ohsawa, and Y Kondo, and H Shiroto, and H Masuko, and T Fukushima, and A Kataoka, and K Ohmori, and Y Sawaguchi, and E Baba, and T Takahashi
First Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan.

We have measured urinary tegafur (FT), 5-FU and uracil concentrations after UFT oral administration (300 mg daily for 7 days) to confirm drug-taking compliance in the 17 cases undergone gastrectomy. Urinary FT and 5-FU concentrations reached to the plateau 2 and 3 days after administration, respectively, and were maintained until the day after termination of administration. Subsequently, FT and 5-FU concentrations also decreased about 50% at 2 day, 20% at 3 day, 10% of the plateau values at 4 day after termination, respectively. The mean plateau value of urinary FT was 12.9 +/- 6.8 micrograms/dl, and that of urinary 5-FU was 0.67 +/- 0.50 microgram/dl. On the other hand, uracil concentration, was not different before and after administration because of the uracil being present endogenously. Therefore, it was suggested that measurement of urinary FT and 5-FU concentrations is useful for confirmation of UFT-taking compliance.

UI MeSH Term Description Entries
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D003187 Compliance Distensibility measure of a chamber such as the lungs (LUNG COMPLIANCE) or bladder. Compliance is expressed as a change in volume per unit change in pressure.
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D005743 Gastrectomy Excision of the whole (total gastrectomy) or part (subtotal gastrectomy, partial gastrectomy, gastric resection) of the stomach. (Dorland, 28th ed) Gastrectomies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.

Related Publications

S Ohsawa, and Y Kondo, and H Shiroto, and H Masuko, and T Fukushima, and A Kataoka, and K Ohmori, and Y Sawaguchi, and E Baba, and T Takahashi
[5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration].
December 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
S Ohsawa, and Y Kondo, and H Shiroto, and H Masuko, and T Fukushima, and A Kataoka, and K Ohmori, and Y Sawaguchi, and E Baba, and T Takahashi
[The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
August 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
S Ohsawa, and Y Kondo, and H Shiroto, and H Masuko, and T Fukushima, and A Kataoka, and K Ohmori, and Y Sawaguchi, and E Baba, and T Takahashi
[Study on the concentrations of 5-fluorouracil (5-FU), tegafur (ET) and uracil in bile: comparison of UFT or FT].
December 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
S Ohsawa, and Y Kondo, and H Shiroto, and H Masuko, and T Fukushima, and A Kataoka, and K Ohmori, and Y Sawaguchi, and E Baba, and T Takahashi
[Blood concentrations of futraful, uracil and 5-fluorouracil (5-FU) after UFT administration in the various reconstructions after gastrectomy. Saitama UFT Research Group].
November 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
S Ohsawa, and Y Kondo, and H Shiroto, and H Masuko, and T Fukushima, and A Kataoka, and K Ohmori, and Y Sawaguchi, and E Baba, and T Takahashi
[Tegafur and 5-FU concentrations in cancerous and normal tissues in nude mice after oral administration of UFT].
December 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
S Ohsawa, and Y Kondo, and H Shiroto, and H Masuko, and T Fukushima, and A Kataoka, and K Ohmori, and Y Sawaguchi, and E Baba, and T Takahashi
[Level of 5-FU in cancerous and normal tissues of nude mice after oral administration of tegafur coadministered with uracil (UFT)].
May 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
S Ohsawa, and Y Kondo, and H Shiroto, and H Masuko, and T Fukushima, and A Kataoka, and K Ohmori, and Y Sawaguchi, and E Baba, and T Takahashi
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
September 1996, Clinical cancer research : an official journal of the American Association for Cancer Research,
S Ohsawa, and Y Kondo, and H Shiroto, and H Masuko, and T Fukushima, and A Kataoka, and K Ohmori, and Y Sawaguchi, and E Baba, and T Takahashi
Effect of gastrectomy on the pharmacokinetics of tegafur, uracil, and 5-fluorouracil after oral administration of a 1:4 tegafur and uracil combination.
January 1994, Cancer chemotherapy and pharmacology,
S Ohsawa, and Y Kondo, and H Shiroto, and H Masuko, and T Fukushima, and A Kataoka, and K Ohmori, and Y Sawaguchi, and E Baba, and T Takahashi
[5-FU, FT-207 and uracil concentrations in the serum and tissues of patients with cervical cancer after UFT oral administration].
February 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
S Ohsawa, and Y Kondo, and H Shiroto, and H Masuko, and T Fukushima, and A Kataoka, and K Ohmori, and Y Sawaguchi, and E Baba, and T Takahashi
[Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer].
January 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!